Company Quick10K Filing
AstraZeneca
20-F 2019-12-31 Filed 2020-03-03
20-F 2018-12-31 Filed 2019-03-05
20-F 2017-12-31 Filed 2018-03-06
20-F 2016-12-31 Filed 2017-03-07
20-F 2015-12-31 Filed 2016-03-08
20-F 2014-12-31 Filed 2015-03-10
20-F 2013-12-31 Filed 2014-03-20
20-F 2012-12-31 Filed 2013-03-25
20-F 2011-12-31 Filed 2012-03-28
20-F 2010-12-31 Filed 2011-04-28
20-F 2009-12-31 Filed 2010-03-25

AZN 20F Annual Report

Part 1
Item 1. Identity of Directors, Senior Management and Advisers
Item 2. Offer Statistics and Expected Timetable
Item 3. Key Information
Item 4. Information on The Company
Item 4A. Unresolved Staff Comments
Item 5. Operating and Financial Review and Prospects
Item 6. Directors, Senior Management and Employees
Item 7. Major Shareholders and Related Party Transactions
Item 8. Financial Information
Item 9. The Offer and Listing
Item 10. Additional Information
Item 11. Quantitative and Qualitative Disclosures About Market Risk
Item 12. Description of Securities Other Than Equity Securities
Part II
Item 13. Defaults, Dividend Arrearages and Delinquencies
Item 14. Material Modifications To The Rights of Security Holders and Use of Proceeds
Item 15. Controls and Procedures
Item 16. Reserved
Item 16A. Audit Committee Financial Expert
Item 16B. Code of Ethics
Item 16C. Principal Accountant Fees and Services
Item 16D. Exemptions From The Listing Standards for Audit Committees
Item 16E. Purchases of Equity Securities By The Issuer and Affiliated Purchasers
Item 16F. Change in Registrant's Certifying Accountant
Item 16G. Corporate Governance
Item 16H. Mine Safety Disclosure
Part III
Item 17. Financial Statements
Item 18. Financial Statements
Item 19. Exhibits(1)
EX-2.1 a20-5700_1ex2d1.htm
EX-8.1 a20-5700_1ex8d1.htm
EX-12.1 a20-5700_1ex12d1.htm
EX-12.2 a20-5700_1ex12d2.htm
EX-13.1 a20-5700_1ex13d1.htm
EX-15.1 a20-5700_1ex15d1.htm
EX-15.2 a20-5700_1ex15d2.htm
EX-15.3 a20-5700_1ex15d3.htm
EX-15.4 a20-5700_1ex15d4.htm

AstraZeneca Earnings 2019-12-31

Balance SheetIncome StatementCash Flow

20-F 1 a20-5700_120f.htm 20-F

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 20-F

 

(Mark One)

 

o

REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES
EXCHANGE ACT OF 1934

 

 

OR

 

 

x

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the fiscal year ended December 31, 2019

 

 

OR

 

 

o

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the transition period from          to            .

 

 

OR

 

 

o

SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

 

Date of event requiring this shell company report

 

Commission file number: 001-11960

 

ASTRAZENECA PLC

(Exact name of Registrant as specified in its charter)

 

England and Wales

(Jurisdiction of incorporation or organization)

 

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

England

(Address of principal executive offices)

 

Adrian Kemp

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

England

Telephone: +44 20 3749 5000

Facsimile number: +44 1223 352 858

(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)

 

Securities registered or to be registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading symbol(s)

 

Name of each exchange on which registered

American Depositary Shares, each representing one half of an Ordinary Share of 25¢ each

 

AZN

 

The New York Stock Exchange

Ordinary Shares of 25¢ each

 

 

 

The New York Stock Exchange*

2.375% Notes due 2020

 

AZN 20

 

The New York Stock Exchange

2.375% Notes due 2022

 

AZN 22A

 

The New York Stock Exchange

Floating Rate Notes due 2022

 

AZN 22B

 

The New York Stock Exchange

3.500% Notes due 2023

 

AZN 23

 

The New York Stock Exchange

7.000% Notes due 2023

 

AZN / 23

 

The New York Stock Exchange

Floating Rate Notes due 2023

 

AZN 23A

 

The New York Stock Exchange

3.375% Notes due 2025

 

AZN 25

 

The New York Stock Exchange

3.125% Notes due 2027

 

AZN 27A

 

The New York Stock Exchange

4.000% Notes due 2029

 

AZN 29

 

The New York Stock Exchange

6.450% Notes due 2037

 

AZN 37

 

The New York Stock Exchange

4.000% Notes due 2042

 

AZN 42

 

The New York Stock Exchange

4.375% Notes due 2045

 

AZN 45

 

The New York Stock Exchange

4.375% Notes due 2048

 

AZN 48

 

The New York Stock Exchange

 


*       Not for trading, but only in connection with the registration of American Depositary Shares representing such Ordinary Shares pursuant to the requirements of the Securities and Exchange Commission.

 


 

Securities registered or to be registered pursuant to Section 12(g) of the Act:

 

None

(Title of Class)

 

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:

 

None

(Title of Class)

 

Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report.

 

The number of outstanding shares of each class of stock of AstraZeneca PLC as of December 31, 2019 was:

 

Title of Class

 

Number of Shares Outstanding

 

Ordinary Shares of 25¢ each:

 

1,312,137,976

 

Redeemable Preference Shares of £1 each:

 

50,000

 

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes x  No o

 

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Yes o  No x

 

Note — Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x  No o

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes x  No o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large Accelerated Filer x

 

Accelerated Filer o

 

Non-accelerated Filer o

 

 

 

 

 

Emerging growth company o

 

 

 

 

 

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act. o

 


† The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

 

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

 

 

o

U.S. GAAP

 

 

 

 

x

International Financial Reporting Standards as issued by the International Accounting Standards Board

 

 

 

 

o

Other

 

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.

o Item 17  o Item 18

 

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes o  No x

 

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.

 

Yes o  No o

 


 

Pursuant to Rule 12b-23(a) of the Securities Exchange Act of 1934, as amended, the information for the 2019 Form 20-F of AstraZeneca PLC (the “Company”) set out below is being incorporated by reference from AstraZeneca’s “Annual Report and Form 20-F Information 2019” included as exhibit 15.1 to this Form 20-F dated and submitted on March 3, 2020.

 

References below to major headings include all information under such major headings, including subheadings, unless such reference is a reference to a subheading, in which case such reference includes only the information contained under such subheading. Unless the context otherwise requires, “AstraZeneca” or “Group” refers to the Company and its consolidated entities. Other information contained within AstraZeneca’s “Annual Report and Form 20-F Information 2019” included as exhibit 15.1 to this Form 20-F, including graphs and tabular data, is not included in this Form 20-F unless specifically identified below. Photographs are also not included.

 

In addition to the information set out below, the information (including tabular data) set forth under the headings “Use of terms” on the inside front cover, “Strategic Report—Financial Review—Measuring performance” on page 80, and the tables on page 81, “Additional Information —Trade Marks” on page 267, “—Glossary” on pages 268 to 271 and “—Important information for readers of this Annual Report—Cautionary statement regarding forward-looking statements”, “—Inclusion of Reported performance, Core financial measures and constant exchange rate growth rates”, “—Statements of competitive position, growth rates and sales”, “— AstraZeneca websites”, “—External/third-party websites” and “—Figures” on page 272, in each case of AstraZeneca’s “Annual Report and Form 20-F Information 2019” included as exhibit 15.1 to this Form 20-F dated March 3, 2020 is incorporated by reference. References herein to AstraZeneca websites are textual references only and information on or accessible through such websites does not form part of and is not incorporated into this Form 20-F dated March 3, 2020.

 

PART 1

 

ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS

 

Not applicable.

 

ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE

 

Not applicable.

 

ITEM 3. KEY INFORMATION

 

A.        Selected Financial Data

 

The information (including graphs and tabular data) set forth under the headings “Financial Statements—Group Financial Record” on page 236, “Additional Information—Shareholder Information—Issued share capital, shareholdings and share prices” and the first table that appears under “—Ordinary Shares in issue” on page 260, in each case of AstraZeneca’s “Annual Report and Form 20-F Information 2019” included as exhibit 15.1 to this Form 20-F dated March 3, 2020 is incorporated by reference. The selected financial data incorporated by reference herein is derived from audited financial statements of the Company and its consolidated entities, prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board and as adopted by the European Union, included in AstraZeneca’s “Annual Report and Form 20-F Information 2019” included as exhibit 15.1 to this Form 20-F dated March 3, 2020.

 

B.        Capitalization and Indebtedness

 

Not applicable.

 

C.        Reason for the Offer and Use of Proceeds

 

Not applicable.

 


 

D.        Risk Factors

 

The information (including tabular data) set forth or referenced under the heading “Additional Information—Risk” on pages 246 to 257 of AstraZeneca’s “Annual Report and Form 20-F Information 2019” included as exhibit 15.1 to this Form 20-F dated March 3, 2020 is incorporated by reference.

 

ITEM 4. INFORMATION ON THE COMPANY

 

A.        History and Development of the Company

 

The information (including tabular data) set forth under the headings “Additional Information—Shareholder Information—History and development of the Company” on page 259, “Strategic Report—Financial Review— Collaboration Revenue” on pages 82 to 83, “Strategic Report—Financial Review—Financial position —31 December 2019— Business combinations” on page 87, “— Investments, divestments and capital expenditure” on pages 89 to 90, “Corporate Governance—Corporate Governance Report—Compliance with the UK Corporate Governance Code—Board Leadership and Company Purpose” on pages 108 to 109 and “Additional Information—Important information for readers of this Annual Report— AstraZeneca websites” on page 272, in each case of AstraZeneca’s “Annual Report and Form 20-F Information 2019” included as exhibit 15.1 to this Form 20-F dated March 3, 2020 is incorporated by reference.

 

The United States Securities and Exchange Commission (the “SEC”) maintains a website at www.sec.gov which contains in electronic form each of the reports and other information that we have filed electronically with the SEC.

 

B.        Business Overview

 

The information (including graphs and tabular data) set forth under the headings “Strategic Report—AstraZeneca at a glance” on pages 2 to 3, “—Chairman’s Statement” on page 4, “—Chief Executive Officer’s Review” on pages 5 to 7, “—Strategy” on pages 17 to 19, “—Key Performance Indicators” on pages 20 to 23, “—Business Review” on pages 24 to 26, “—Therapy Area Review” on pages 54 to 73, “— Risk Overview—Managing risk”, “—Risk Overview— Emerging risks” on page 74, “—Risk management embedded in business processes” on pages 74 to 75, “—Brexit” on page 75, “Corporate Governance—Corporate Governance Report—Other Governance information—Global Compliance and Internal Audit Services (IA)” on page 112, “Additional Information— Development Pipeline as at 31 December 2019” on pages 238 to 242, “—Patent Expiries of Key Marketed Products” on pages 243 to 245, “—Sustainability: supplementary information” on page 266, “Financial Statements—Notes to the Group Financial Statements—Note 1—Revenue” on pages 180 to 181, “—Note 6 —Segment information” on pages 185 to 187, and “Additional Information— Important information for readers of this Annual Report—Statements of competitive position, growth rates and sales” on page 272, in each case of AstraZeneca’s “Annual Report and Form 20-F Information 2019” included as exhibit 15.1 to this Form 20-F dated March 3, 2020 is incorporated by reference.

 

On February 25, 2020, AstraZeneca announced that it had divested its global rights to Movantik (naloxegol), excluding Europe, Canada and Israel, to RedHill Biopharma (RedHill). Movantik is a peripherally acting mu-opioid receptor antagonist (PAMORA) indicated for the treatment of opioid-induced constipation (OIC).

 

On March 2, 2020, AstraZeneca announced that it had completed a previously communicated agreement with Atnahs Pharma (Atnahs) to divest its global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination).

 

Geographical Review

 

This section Item 4—“Information on the Company— Business Overview—Geographical Review” should be read in conjunction with Item 5—“Operating and Financial Review and Prospects—Operating Results” below.

 

2


 

 

 

World

 

Emerging Markets

 

U.S.

 

Europe

 

Established ROW

 

2019

 

Sales
$m

 

Actual
%

 

CER
%

 

Sales
$m

 

Actual
%

 

CER
%

 

Sales
$m

 

Actual
%

 

Sales
$m

 

Actual
%

 

CER
%

 

Sales
$m

 

Actual
%

 

CER
%

 

Oncology:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tagrisso

 

3,189

 

71

 

74

 

762

 

n/m

 

n/m

 

1,268

 

46

 

474

 

51

 

59

 

685

 

n/m

 

n/m

 

Imfinzi

 

1,469

 

n/m

 

n/m

 

30

 

n/m

 

n/m

 

1,041

 

85

 

179

 

n/m

 

n/m

 

219

 

n/m

 

n/m

 

Lynparza

 

1,198

 

85

 

89

 

133

 

n/m

 

n/m

 

626

 

81

 

287

 

51

 

59

 

152

 

n/m

 

n/m

 

Calquence

 

164

 

n/m

 

n/m

 

2

 

n/m

 

n/m

 

162

 

n/m

 

 

n/m

 

n/m

 

 

n/m

 

n/m

 

Faslodex

 

892

 

(13

)

(11

)

198

 

29

 

36

 

328

 

(39

)

229

 

3

 

9

 

137

 

19

 

17

 

Zoladex

 

813

 

8

 

13

 

492

 

20

 

28

 

7

 

(17

)

135

 

2

 

7

 

179

 

(11

)

(10

)

Iressa

 

423

 

(18

)

(15

)

286

 

 

4

 

17

 

(33

)

70

 

(36

)

(32

)

50

 

(49

)

(49

)

Arimidex

 

225

 

6

 

11

 

152

 

15

 

21

 

 

n/m

 

28

 

(8

)

(3

)

45

 

(9

)

(9

)

Casodex

 

200

 

 

3

 

127

 

13

 

19

 

 

(88

)

16

 

(20

)

(15

)

57

 

(15

)

(15

)

Others

 

94

 

(18

)

(17

)

29

 

(6

)

(3

)

 

n/m

 

5

 

(24

)

(19

)

60

 

(21

)

(22

)

Total Oncology

 

8,667

 

44

 

47

 

2,211

 

45

 

52

 

3,449

 

43

 

1,423

 

35

 

42

 

1,584

 

53

 

52

 

CVRM:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Farxiga

 

1,543

 

11

 

14

 

471

 

40

 

48

 

537

 

(9

)

373

 

18

 

25

 

162

 

9

 

10

 

Brilinta

 

1,581

 

20

 

23

 

462

 

42

 

49

 

710

 

21

 

351

 

1

 

7

 

58

 

(1

)

3

 

Bydureon

 

549

 

(6

)

(5

)

11

 

34

 

39

 

459

 

(3

)

66

 

(19

)

(14

)

13

 

(32

)

(28

)

Onglyza

 

527

 

(3

)

 

176

 

3

 

9

 

230

 

3

 

70

 

(22

)

(17

)

51

 

(14

)

(12

)

Byetta

 

110

 

(13

)

(11

)

12

 

47

 

60

 

68

 

(9

)

19

 

(35

)

(31

)

11

 

(24

)

(20

)

Other diabetes

 

52

 

33

 

35

 

1

 

n/m

 

n/m

 

40

 

18

 

9

 

88

 

n/m

 

2

 

23

 

33

 

Lokelma

 

14

 

n/m

 

n/m

 

 

 

 

13

 

n/m

 

1

 

n/m

 

n/m

 

 

 

 

Crestor

 

1,278

 

(11

)

(8

)

806

 

(4

)

 

104

 

(39

)

148

 

(27

)

(23

)

220

 

 

1

 

Seloken/Toprol-XL

 

760

 

7

 

12

 

686

 

7

 

13

 

37

 

(5

)

25

 

31

 

31

 

12

 

(11

)

(8

)

Atacand

 

221

 

(15

)

(11

)

160

 

2

 

7

 

12

 

(11

)

30

 

(57

)

(57

)

19

 

1

 

7

 

Others

 

271

 

(9

)

(6

)

193

 

(6

)

(3

)

(1

)

(91

)

59

 

(16

)

(12

)

20

 

(16

)

(16

)

Total CVRM

 

6,906

 

3

 

6

 

2,978

 

10

 

16

 

2,209

 

n/m

 

1,151

 

(6

)

(1

)

568

 

(2

)

n/m

 

Respiratory:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Symbicort

 

2,495

 

(3

)

 

547

 

11

 

17

 

829

 

(4

)

678

 

(12

)

(7

)

441

 

2

 

3

 

Pulmicort

 

1,466

 

14

 

18

 

1,190

 

20

 

24

 

110

 

(5

)

81

 

(10

)

(4

)

85

 

1

 

1

 

Fasenra

 

704

 

n/m

 

n/m

 

5

 

n/m

 

n/m

 

482

 

n/m

 

118

 

n/m

 

n/m

 

99

 

n/m

 

n/m

 

Daliresp/Daxas

 

215

 

14

 

15

 

4

 

(18

)

(13

)

184

 

19

 

26

 

(8

)

(3

)

1

 

32

 

35

 

Duaklir

 

77

 

(19

)

(15

)

1

 

44

 

49

 

3

 

 

71

 

(22

)

(17

)

2

 

(65

)

(64

)

Bevespi

 

42

 

26

 

26

 

 

n/m

 

n/m

 

42

 

25

 

 

n/m

 

n/m

 

 

n/m

 

n/m

 

Breztri

 

2

 

n/m

 

n/m

 

 

 

 

 

 

 

 

 

2

 

n/m

 

n/m

 

Others

 

390

 

(13

)

(9

)

240

 

62

 

70

 

3

 

(88

)

133

 

(38

)

(35

)

14

 

(74

)

(73

)

Total Respiratory

 

5,391

 

10

 

13

 

1,987

 

21

 

27

 

1,653

 

17

 

1,107

 

(10

)

(5

)

644

 

4

 

4

 

Other:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nexium

 

1,483

 

(13

)

(11

)

748

 

8

 

14

 

218

 

(29

)

63

 

(73

)

(72

)

454

 

(4

)

(4

)

Synagis

 

358

 

(46

)

(46

)

 

(100

)

(100

)

46

 

(84

)

312

 

(17

)

(17

)

 

n/m

 

n/m

 

Losec/Prilosec

 

263

 

(3

)

1

 

179

 

11

 

17

 

10

 

43

 

49

 

(30

)

(26

)

25

 

(27

)

(26

)

Seroquel XR/IR

 

191

 

(47

)

(46

)

50

 

(58

)

(57

)

34

 

(69

)

88

 

(18

)

(14

)

19

 

(30

)

(30

)

Others

 

306

 

(23

)

(20

)

12

 

(77

)

(81

)

128

 

(4

)

157

 

(1

)

2

 

9

 

(84

)

(67

)

Total Other

 

2,601

 

(24

)

(21

)

989

 

(3

)

1

 

436

 

(48

)

669

 

(29

)

(28

)

507

 

(14

)

(12

)

Total Product Sales

 

23,565

 

12

 

15

 

8,165

 

18

 

24

 

7,747

 

13

 

4,350

 

(2

)

2

 

3,303

 

17

 

18

 

 

3


 

 

 

World

 

Emerging Markets

 

U.S.

 

Europe

 

Established ROW

 

2018

 

Sales
$m

 

Actual
%

 

CER
%

 

Sales
$m

 

Actual
%

 

CER
%

 

Sales
$m

 

Actual
%

 

Sales
$m

 

Actual
%

 

CER
%

 

Sales
$m

 

Actual
%

 

CER
%

 

Oncology:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tagrisso

 

1,860

 

95

 

93

 

347

 

n/m

 

n/m

 

869

 

n/m

 

314

 

68

 

61

 

330

 

45

 

43

 

Imfinzi

 

633

 

n/m

 

n/m

 

6

 

n/m

 

n/m

 

564

 

n/m

 

27

 

n/m

 

n/m

 

36

 

n/m

 

n/m

 

Lynparza

 

647

 

n/m

 

n/m

 

51

 

n/m

 

n/m

 

345

 

n/m

 

190

 

46

 

41

 

61

 

n/m

 

n/m

 

Calquence

 

62

 

n/m

 

n/m

 

 

 

 

62

 

n/m

 

 

 

 

 

 

 

Faslodex

 

1,028

 

9

 

9

 

154

 

34

 

41

 

537

 

9

 

221

 

(14

)

(19

)

116

 

49

 

46

 

Zoladex

 

752

 

2

 

2

 

409

 

16

 

18

 

8

 

(47

)

133

 

(6

)

(10

)

202

 

(11

)

(12

)

Iressa

 

518

 

(2

)

(4

)

286

 

14

 

12

 

26

 

(33

)

109

 

(3

)

(8

)

97

 

(23

)

(25

)

Arimidex

 

212

 

(2

)

(3

)

132

 

12

 

11

 

 

n/m

 

31

 

(9

)

(9

)

49

 

(16

)

(17

)

Casodex

 

201

 

(7

)

(8

)

113

 

5

 

2

 

1

 

n/m

 

20

 

(9

)

(9

)

67

 

(22

)

(23

)

Others

 

115

 

1

 

(1

)

30

 

29

 

30

 

 

 

8

 

20

 

20

 

77

 

(7

)

(8

)

Total Oncology

 

6,028

 

50

 

49

 

1,528

 

36

 

37

 

2,412

 

n/m

 

1,053

 

19

 

14

 

1,035

 

16

 

14

 

CVRM:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Farxiga

 

1,391

 

30

 

30

 

336

 

45

 

52

 

591

 

21

 

315

 

30

 

24

 

149

 

34

 

34

 

Brilinta

 

1,321

 

22

 

21

 

326

 

46

 

48

 

588

 

16

 

348

 

18

 

13

 

59

 

16

 

16

 

Bydureon

 

584

 

2

 

1

 

8

 

(11

)

(11

)

475

 

4

 

81

 

(8

)

(13

)

20

 

5

 

5

 

Onglyza

 

543

 

(11

)

(11

)

172

 

32

 

34

 

223

 

(30

)

89

 

(14

)

(18

)

59

 

4

 

4

 

Byetta

 

126

 

(28

)

(28

)

8

 

(33

)

(33

)

74

 

(35

)

29

 

(15

)

(15

)

15

 

(6

)

(6

)

Other diabetes

 

39

 

(26

)

(26

)

(1

)

n/m

 

n/m

 

34

 

(35

)

5

 

n/m

 

n/m

 

1

 

n/m

 

n/m

 

Lokelma

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Crestor

 

1,433

 

(39

)

(40

)

841

 

7

 

7

 

170

 

(54

)

203

 

(70

)

(71

)

219

 

(60

)

(60

)

Seloken/Toprol-XL

 

712

 

2

 

4

 

641

 

8

 

10

 

39

 

5

 

19

 

(63

)

(63

)

13

 

 

 

Atacand

 

260

 

(13

)

(12

)

157

 

(12

)

(7

)

13

 

(32

)

70

 

(19

)

(20

)

20

 

18

 

18

 

Others

 

301

 

(11

)

(12

)

207

 

1

 

 

(1

)

n/m

 

71

 

(17

)

(23

)

24

 

(44

)

(44

)

Total CVRM

 

6,710

 

(8

)

(8

)

2,695

 

14

 

15

 

2,206

 

(7

)

1,230

 

(26

)

(29

)

579

 

(33

)

(34

)

Respiratory:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Symbicort

 

2,561

 

(9

)

(10

)

495

 

13

 

14

 

862

 

(22

)

773

 

(6

)

(10

)

431

 

(3

)

(4

)

Pulmicort

 

1,286

 

9

 

8

 

995

 

18

 

17

 

116

 

(26

)

90

 

(2

)

(8

)

85

 

(3

)

(5

)

Fasenra

 

297

 

n/m

 

n/m

 

1

 

n/m

 

n/m

 

218

 

n/m

 

32

 

n/m

 

n/m

 

46

 

n/m

 

n/m

 

Daliresp/ Daxas

 

189

 

(5

)

(5

)

5

 

25

 

25

 

155

 

(7

)

28

 

8

 

4

 

1

 

 

 

Duaklir

 

95

 

20

 

14

 

1

 

n/m

 

n/m

 

 

 

91

 

18

 

12

 

3

 

50

 

50

 

Bevespi

 

33

 

n/m

 

n/m

 

 

 

 

33

 

n/m

 

 

 

 

 

 

 

Breztri

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Others

 

450

 

4

 

2

 

147

 

40

 

38

 

32

 

(55

)

215

 

6

 

3

 

56

 

 

 

Total Respiratory

 

4,911

 

4

 

3

 

1,644

 

18

 

18

 

1,416

 

(6

)

1,229

 

1

 

(4

)

622

 

5

 

4

 

Other:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nexium

 

1,702

 

(13

)

(14

)

690

 

1

 

1

 

306

 

(39

)

235

 

(6

)

(11

)

471

 

(10

)

(11

)

Synagis

 

665

 

(3

)

(3

)

1

 

n/m

 

n/m

 

287

 

(9

)

377

 

2

 

2

 

 

 

 

Losec/Prilosec

 

272

 

 

(2

)

161

 

15

 

11

 

7

 

(36

)

70

 

(9

)

(12

)

34

 

(21

)

(21

)

Seroquel XR / IR

 

361

 

(29

)

(31

)

118

 

(22

)

(23

)

108

 

(44

)

107

 

(16

)

(20

)

28

 

(26

)

(26

)

Others

 

400

 

(46

)

(46

)

54

 

(82

)

(78

)

134

 

(9

)

158

 

(7

)

(14

)

54

 

(56

)

(57

)

Total Other

 

3,400

 

(18

)

(19

)

1,024

 

(19

)

(19

)

842

 

(28

)

947

 

(5

)

(8

)

587

 

(19

)

(20

)

Total Product Sales

 

21,049

 

4

 

4

 

6,891

 

12

 

13

 

6,876

 

11

 

4,459

 

(6

)

(10

)

2,823

 

(8

)

(9

)

 

4


 

 

 

World

 

Emerging Markets

 

U.S.

 

Europe

 

Established ROW

 

2017

 

Sales
$m

 

Actual
%

 

CER
%

 

Sales
$m

 

Actual
%

 

CER
%

 

Sales
$m

 

Actual
%

 

Sales
$m

 

Actual
%

 

CER
%

 

Sales
$m

 

Actual
%

 

CER
%

 

Oncology:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tagrisso

 

955

 

126

 

126

 

135

 

n/m

 

n/m

 

405

 

59

 

187

 

146

 

142

 

228

 

175

 

183

 

Imfinzi

 

19

 

n/m

 

n/m

 

 

 

 

19

 

n/m

 

 

 

 

 

 

 

Lynparza

 

297

 

36

 

35

 

18

 

n/m

 

n/m

 

141

 

11

 

130

 

60

 

58

 

8

 

n/m

 

n/m

 

Calquence

 

3

 

n/m

 

n/m

 

 

 

 

3

 

n/m

 

 

 

 

 

 

 

Faslodex

 

941

 

13

 

13

 

115

 

20

 

18

 

492

 

12

 

256

 

12

 

11

 

78

 

15

 

18

 

Zoladex

 

735

 

(10

)

(10

)

353

 

(1

)

(1

)

15

 

(57

)

141

 

(10

)

(8

)

226

 

(16

)

(15

)

Iressa

 

528

 

3

 

3

 

251

 

8

 

8

 

39

 

70

 

112

 

(7

)

(8

)

126

 

(8

)

(6

)

Arimidex

 

217

 

(6

)

(4

)

118

 

7

 

10

 

7

 

(50

)

34

 

(8

)

(8

)

58

 

(18

)

(15

)

Casodex

 

215

 

(13

)

(11

)

108

 

1

 

4

 

(1

)

n/m

 

22

 

(19

)

(19

)

86

 

(23

)

(21

)

Others

 

114

 

10

 

13

 

28

 

12

 

16

 

 

 

3

 

(63

)

(63

)

83

 

17

 

20

 

Total Oncology

 

4,024

 

19

 

19

 

1,126

 

19

 

20

 

1,120

 

25

 

885

 

21

 

20

 

893

 

10

 

12

 

CVRM:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Farxiga

 

1,074

 

29

 

28

 

232

 

74

 

73

 

489

 

7

 

242

 

29

 

28

 

111

 

91

 

90

 

Brilinta

 

1,079

 

29

 

29

 

224

 

19

 

21

 

509

 

46

 

295

 

14

 

13

 

51

 

16

 

11

 

Bydureon

 

574

 

(1

)

(1

)

9

 

125

 

75

 

458

 

(1

)

88

 

(12

)

(11

)

19

 

73

 

73

 

Onglyza

 

611

 

(15

)

(16

)

130

 

(8

)

(10

)

320

 

(15

)

104

 

(21

)

(21

)

57

 

(19

)

(20

)

Byetta

 

176

 

(31

)

(30

)

12

 

(50

)

(50

)

114

 

(30

)

34

 

(24

)

(22

)

16

 

(24

)

(24

)

Other diabetes

 

53

 

33

 

33

 

1

 

n/m

 

n/m

 

52

 

30

 

 

 

 

 

 

 

Lokelma

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Crestor

 

2,365

 

(30

)

(30

)

784

 

9

 

11

 

373

 

(70

)

666

 

(23

)

(23

)

542

 

(8

)

(6

)

Seloken/Toprol-XL

 

695

 

(6

)

(4

)

593

 

11

 

12

 

37

 

(61

)

52

 

(42

)

(41

)

13

 

(19

)

(19

)

Atacand

 

300

 

(5

)

(3

)

178

 

10

 

12

 

19

 

(47

)

86

 

(11

)

(11

)

17

 

(15

)

(15

)

Others

 

339

 

(6

)

(5

)

204

 

(11

)

(7

)

 

 

92

 

(23

)

(24

)

43

 

(14

)

(12

)

Total CVRM

 

7,266

 

(10

)

(10

)

2,367

 

11

 

12

 

2,371

 

(26

)

1,659

 

(12

)

(13

)

869

 

(1

)

 

Respiratory:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Symbicort

 

2,803

 

(6

)

(6

)

439

 

9

 

10

 

1,099

 

(12

)

819

 

(10

)

(10

)

446

 

2

 

2

 

Pulmicort

 

1,176

 

11

 

12

 

840

 

20

 

23

 

156

 

(10

)

92

 

(7

)

(8

)

88

 

(2

)

(1

)

Fasenra

 

1

 

n/m

 

n/m

 

 

 

 

1

 

n/m

 

 

 

 

 

 

 

Daliresp/Daxas

 

198

 

29

 

28

 

4

 

 

 

167

 

25

 

26

 

73

 

73

 

1

 

 

 

Duaklir

 

79

 

25

 

25

 

 

n/m

 

n/m

 

 

 

77

 

24

 

24

 

2

 

 

 

Bevespi

 

16

 

n/m

 

n/m

 

 

 

 

16

 

n/m

 

 

 

 

 

 

 

Breztri